


ground state binding
[E-S]



transition state binding
[E-S][‡]
R = aglycon residue




FIG. 1




FIG. 2

compd	K_i (μ M)				
	α -glucosidase ^a	β -glucosidase ^b	β -N-acetylglucosaminidase	β -N-acetylhexosaminidase	
	<i>Saccaromyces sp</i>	sweet almond	bovine kidney ^c	human placenta A ^d	p ^e
1 ^f	330	50	^h	-	-
2 ^f	28	2.6	-	-	-
3	380	*g	2.9 x 10 ⁻¹	2.2 x 10 ⁻¹	2.6 x 10 ⁻¹
4	ni	ni	1.1 x 10 ⁻¹	1.4 x 10 ⁻¹	8.0 x 10 ⁻²
5	ni	ni	1.3	5.1 x 10 ⁻¹	2.4 x 10 ⁻¹
6	*	2.2	*	-	-
7	*	45	*	-	-
8	ni	120	ni ⁱ	-	-
9	53	37	-	-	-

3 / 20

^a K_m = 0.30 mM, V_{max} = 0.7 (μ M/s)/mg. ^b K_m = 3.2 mM, V_{max} = 3.2 (μ M/s)/mg. ^c K_m = 4.1 mM, V_{max} = 6.4 (μ M/s)/mg. ^d K_m = 2.5 mM, V_{max} = 2.1 (μ M/s)/mg. ^e K_m = 2.8 mM, V_{max} = 2.3 (μ M/s)/mg. ^f Preliminary assay result using photometric assay gave K_i values: 430 and 18 μ M for compound 1 and 7.2 and 7.6 μ M for compound 2 toward α -glucosidase and β -glucosidase, respectively. See also refs 6a and 19. ^g *: poor inhibitor with IC₅₀ above 0.5 mM. ^h -: not tested. ⁱ ni: not inhibitor.

FIG. 3






FIG. 4


5 / 20



a $\text{Ph}_3\text{P}^+=\text{CHCO}_2\text{Me} \cdot ^-\text{OAc}$ / benzene; b DIBAL / CH_2Cl_2 ; c TBDMSCl - Et_3N - DMAP / DMF;
 d $\text{ClCH}_2\text{SO}_2\text{Cl}$ - Pyr.; e CsOAc - 18-crown-6 / toluene; f NaOMe; g 1N-HCl / THF; h
 $t\text{-BuOOH}$ - $\text{Ti}(\text{O-}i\text{-Pr})_4$ - L-(+)-diethyltartrate - MS 4A / CH_2Cl_2 ; i $t\text{-BuOOH}$ - $\text{Ti}(\text{O-}i\text{-Pr})_4$ -
 D-(-)-diethyltartrate - MS 4A / CH_2Cl_2 ; j NaN_3 / DMF; k Ph_3P / THF; l H_2 - Pd/C / MeOH.

FIG. 5


6 / 20



a $(\text{Boc})_2\text{O} - \text{Et}_3\text{N} / \text{CH}_2\text{Cl}_2$; b $\text{Pb}(\text{OAc})_4 / \text{toluene}$; c $\text{DIBAL} / \text{CH}_2\text{Cl}_2$; d $\text{MsCl} - \text{Et}_3\text{N} / \text{CH}_2\text{Cl}_2$;
 e $\text{NaN}_3 / \text{DMF}$; f 1) $\text{LiAlH}_4 / \text{THF}$, 2) $(\text{Boc})_2\text{O} - \text{Et}_3\text{N} / \text{CH}_2\text{Cl}_2$; g $\text{H}_2 - \text{Pd/C} / \text{MeOH}$; h $\text{Ac}_2\text{O} - \text{Pyr.}$;
 i 1) $\text{H}_2 - \text{Pd/C} / \text{MeOH} - \text{HCl}$, 2) TFA ; j TFA ; k CH_2O or $\text{CH}_3(\text{CH}_2)_2\text{CHO} - \text{NaBH}_3\text{CN} / \text{MeOH}$; l
 $\text{H}_2 - \text{Pd/C} / \text{MeOH} - \text{HCl}$; m $\text{TsCl} - \text{Pyr.}$; n $\text{BnBr} - \text{Ag}_2\text{O} - \text{KI} / \text{DMF}$; o 1) CH_2O or $\text{CH}_3\text{CHO} - \text{NaBH}_3\text{CN} / \text{MeOH}$, 2) $\text{H}_2 - \text{Pd/C} / \text{MeOH} - \text{HCl}$.

FIG. 6

7 / 20



a $\text{NH}_4\text{OAc} - \text{NaBH}_3\text{CN} / \text{MeOH}$; *b* $(\text{Boc})_2\text{O} - \text{Et}_3\text{N} / \text{CH}_2\text{Cl}_2$; *c* 1) $\text{Pd/C} / \text{MeOH} - \text{HCl}$, 2) TFA .

FIG. 7




FIG. 8

9/20







FIG. 9




104




103




4




3




108



107











106



105

FIG. 10

					
	3	4	103	104	
Ki	—	24nM	—	—	
					
	105	106	107	108	
Ki	1200nM	860nM	IC ₅₀ MUG<IC ₅₀ MUGS ~ 10μm	IC ₅₀ MUG=100μm IC ₅₀ MUGS<10μm	
—	Not assayed yet				

11 / 20

FIG. 11

EFFECT OF SELECTED HEXOSAMINIDASE INHIBITORS ON INTRACELLULAR
HEXOSAMINIDASE ACTIVITY






FIG. 12

13 / 20



ENZYME - HUMAN PLACENTAL HEXOSAMINIDASE A
INHIBITOR - N - ACETYLGLUCOSAMINE - THIAZOLINE



—◆— MUG
- - -■- - MUGS

FIG. 13A

ENZYME - HUMAN PLACENTAL HEXOSAMINIDASE A
INHIBITOR - N - ACETYLGLUCOSAMINE - THIAZOLINE - 6 SULFATE



—◆— MUG
- - -■- - MUGS

FIG. 13B

14 / 20





FIG. 14

a. $\text{Me}_3\text{S}^+/\text{NaH}$, DMSO/THF; b. NaN_3 , acetone/ H_2O , 82% from 110; c. MsCl , Pyr. 96%; d. HMTA, NaI/EtOH ; HCl, 65°C; e. isopropenyl acetate, 85% from 113; f. O_3 , Me_2S ; g. DHAP, RAMA, pH=6.5; acid pasc 37°C, pH=4.7; 44% for (R), 30% for (S); h. $\text{Pd-C}/\text{H}_2$, 80%; i. CH_2O , $\text{Pd-C}/\text{H}_2$, 90%.



a. MsCl, Pyr, NaN₃, CH₂Cl₂, 87% for 2 steps; b. PPh₃, THF, Ac₂O, Pyr, 87% from 118; c. Pd-C/H₂ 50 psi, 89%.

FIG. 15

16 / 20





FIG. 16


a. H_2O_2 , PhCN; NaN_3 , NaCN , Ac_2O , Pyr. 76% for 3 steps; b. PS-80, pH=7.0, 45%, 98% ee; c. Ph_3P , toluene, 120°C ; d. Ac_2O , K_2CO_3 , 30% for 2 steps; e. NaN_3 , $\text{ZnCl}_2/\text{Et}_2\text{O}$, DMF 75°C , 62%; f. pH=1, 45°C ; DHAP, RAMA, pH=6.5; g. acid phase, 37°C , 55% for 3 steps; h. Pd-C/ H_2 , 87%; CH_2O , Pd-C/ H_2 , 92%.

17 / 20




a. Lawesson's reagent, toluene, 80°C; b. MeONa/MeOH, 85% for 2 steps; c. SO₃·NMe₃, Pyr. 0°C, 87%.

FIG. 17




a. TBDMSO, TEA, 0°C, DMF, overnight, 88%; b. Ac₂O, Pyridine, 0°C-rt.; c. AcOH/H₂O/THF(5:1:3), 50°C. overnight, 75% for two steps; d. SO₃/Pyr, pyridine, 25 °C. 82%; e. cat. MeONa, MeOH, 85%

FIG. 18



a. TBDMSOTf, TEA, 0 °C, DMF, 1.0 h, 90%; b. BnBr, NaH, 0 °C - 25 °C, 90%; c. TBAF, THF, 0 °C - 25 °C, 4h, 80%; d. SO₃/Pyr, pyridine, 25 °C, 80%; e. Pd(OH)₂/C, H₂, 75%

FIG. 19



a. MeOH, 50°C, 1h, 90%; b. MeONa (cat.), MeOH, 3h, 80%.

FIG. 20